Targeting retrovirus entry

F. L. Cosset, Stephen J Russell

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Most of the clinical gene therapy trials that have been initiated to date have employed ex vivo strategies in which cells are genetically modified outside the body and reimplanted. The ability to deliver genes accurately and efficiently to selected target cell populations in vivo would greatly expand the scope of gene therapy, but current vectors are not well suited to this task. Here we review recent attempts to develop retroviral vectors incorporating engineered envelope glycoproteins that are capable of delivering their genes in a highly specific manner to selected human target cells.

Original languageEnglish (US)
Pages (from-to)946-956
Number of pages11
JournalGene Therapy
Volume3
Issue number11
StatePublished - 1996
Externally publishedYes

Fingerprint

Retroviridae
Genetic Therapy
Health Services Needs and Demand
Genes
Glycoproteins

Keywords

  • Gene delivery
  • Gene therapy
  • Retroviral display
  • Retroviral vectors
  • Targeting

ASJC Scopus subject areas

  • Genetics

Cite this

Cosset, F. L., & Russell, S. J. (1996). Targeting retrovirus entry. Gene Therapy, 3(11), 946-956.

Targeting retrovirus entry. / Cosset, F. L.; Russell, Stephen J.

In: Gene Therapy, Vol. 3, No. 11, 1996, p. 946-956.

Research output: Contribution to journalArticle

Cosset, FL & Russell, SJ 1996, 'Targeting retrovirus entry', Gene Therapy, vol. 3, no. 11, pp. 946-956.
Cosset FL, Russell SJ. Targeting retrovirus entry. Gene Therapy. 1996;3(11):946-956.
Cosset, F. L. ; Russell, Stephen J. / Targeting retrovirus entry. In: Gene Therapy. 1996 ; Vol. 3, No. 11. pp. 946-956.
@article{28e18f35085d4903ae8a2f277aab1d08,
title = "Targeting retrovirus entry",
abstract = "Most of the clinical gene therapy trials that have been initiated to date have employed ex vivo strategies in which cells are genetically modified outside the body and reimplanted. The ability to deliver genes accurately and efficiently to selected target cell populations in vivo would greatly expand the scope of gene therapy, but current vectors are not well suited to this task. Here we review recent attempts to develop retroviral vectors incorporating engineered envelope glycoproteins that are capable of delivering their genes in a highly specific manner to selected human target cells.",
keywords = "Gene delivery, Gene therapy, Retroviral display, Retroviral vectors, Targeting",
author = "Cosset, {F. L.} and Russell, {Stephen J}",
year = "1996",
language = "English (US)",
volume = "3",
pages = "946--956",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Targeting retrovirus entry

AU - Cosset, F. L.

AU - Russell, Stephen J

PY - 1996

Y1 - 1996

N2 - Most of the clinical gene therapy trials that have been initiated to date have employed ex vivo strategies in which cells are genetically modified outside the body and reimplanted. The ability to deliver genes accurately and efficiently to selected target cell populations in vivo would greatly expand the scope of gene therapy, but current vectors are not well suited to this task. Here we review recent attempts to develop retroviral vectors incorporating engineered envelope glycoproteins that are capable of delivering their genes in a highly specific manner to selected human target cells.

AB - Most of the clinical gene therapy trials that have been initiated to date have employed ex vivo strategies in which cells are genetically modified outside the body and reimplanted. The ability to deliver genes accurately and efficiently to selected target cell populations in vivo would greatly expand the scope of gene therapy, but current vectors are not well suited to this task. Here we review recent attempts to develop retroviral vectors incorporating engineered envelope glycoproteins that are capable of delivering their genes in a highly specific manner to selected human target cells.

KW - Gene delivery

KW - Gene therapy

KW - Retroviral display

KW - Retroviral vectors

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=0029857689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029857689&partnerID=8YFLogxK

M3 - Article

C2 - 8940634

AN - SCOPUS:0029857689

VL - 3

SP - 946

EP - 956

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 11

ER -